On October 14, 2016, the Board of Directors of NanoVibronix Inc. appointed Christopher M. Fashek as a director of the Company and chairman of the Board, effective as of the same date, with a term expiring at the next annual meeting of the Company's stockholders or when his successor is duly elected and qualified. On October 13, 2016, the Board appointed Brian M. Murphy as a director and chief executive officer of the Company, effective as of the same date. The term of Mr. Murphy's employment as the chief executive officer of the Company is 3 years unless earlier terminated, and Mr. Murphy's term as a director shall expire at the next annual meeting of the Company's stockholders or when his successor is duly elected and qualified.

Mr. Murphy, 59, has over 25 years of sales, operations and general management experience in medical devices and medical technology fields. From 2012 to 2016, Mr. Murphy served as national director of commercial sales and national director of national accounts at MiMedx Group Inc. In connection with the appointment of the Company's new chief executive officer, on October 13, 2016, the Board accepted the resignation of William Stern, the Company's current chief executive officer, from his position as the chief executive officer, and the Board appointed Mr. Stern as the Company's president and vice chairman of the Board, effective as of October 13, 2016.